Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in NSCLC Patients With Uncommon EGFR Mutations
NCT03424759Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03424759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424759.